一项随机、盲法、平行对照Ⅰ期临床试验评估23价肺炎球菌多糖疫苗在2岁及以上健康人群中的安全性和初步免疫原性
本研究为随机、盲法、平行对照Ⅰ期临床试验,受试者按1:1随机接种试验疫苗或对照疫苗,观察接种后30分钟、0-7天、8-28天不良事件及第4天血生化血常规异常,记录6个月严重不良事件,并在接种前及第28天用ELISA检测血清抗体。最常见不良反应为注射部位疼痛,其次为红斑,两组全身不良反应发生率无显著差异,未见严重不良反应;两组各血清型IgG特异性抗体几何平均浓度较接种前均升高,血清型4和20的血清阳转率两组间有统计学差异。结论认为该候选疫苗在2岁及以上人群中安全性良好并显示良好免疫原性。
要点
- 最常见不良反应为注射部位疼痛,其次为红斑,两组全身不良反应发生率无显著差异。
- 试验中观察到的不良反应均为常见疫苗接种相关反应,未见严重不良反应。
- 两组各血清型IgG特异性抗体几何平均浓度较接种前均升高,血清型4和20的血清阳转率两组间有统计学差异。
核心结论
- 本临床研究显示,Ab&b Biotechnology Co., Ltd.生产的PPV23候选疫苗在2岁及以上人群接种后安全性良好,同时显示出良好免疫原性。
研究设计与样本
- 随机、盲法、平行对照Ⅰ期临床试验,受试者按1:1随机接受一剂试验疫苗或对照疫苗肌肉注射。
主要发现
- 最常见不良反应为注射部位疼痛,其次为红斑。
- 两组全身不良反应发生率无显著差异。
- 试验中观察到的不良反应均为常见疫苗接种相关反应,未见严重不良反应。
- 与接种前相比,试验组和对照组各血清型IgG特异性抗体几何平均浓度均升高。
- 血清型4和20的血清阳转率在两组间有统计学差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite some progress in pneumococcal immunization, the global burden of pneumococcal infection remains high, and pneumococcal disease remains a public health concern. Studies in China and abroad have found that 23-valent pneumococcal polysaccharide vaccine (PPV23) vaccination can effectively prevent invasive pneumococcal disease. This phase Ⅰ clinical study assessed the safety and immunogenicity of a PPV23 vaccine candidate. METHODS: All subjects were randomly assigned to receive one dose intramuscular injection of experimental vaccine or control vaccine at a ratio of 1:1. The incidence of any adverse events was observed within 30 min, 0-7 days and 8-28 days post vaccination and the incidence of abnormal blood biochemical and blood routine indicators were tested on the 4th day post vaccination, the incidence of serious adverse events (SAEs) at 6 months post vaccination was recorded. Blood samples were collected prior to vaccination and on the 28th day post vaccination, and serum antibodies were detected by enzyme linked immunosorbent assay (ELISA). RESULTS: The most common adverse reaction was pain at the injection site, followed by erythema. There was no significant difference of the incidence of systemic adverse reactions between the two vaccine groups. The adverse reactions observed in the trial were all common vaccination-related reactions, and no serious adverse reactions were observed. Compared to pre-vaccination, the (geometric mean concentrations) GMCs of IgG (immunoglobulin G) specific antibody against each serotype were all increased in the experimental group and the control group, there were statistical differences in seroconversion rates of serotypes 4 and 20 between the two vaccine groups. CONCLUSION: This clinical study showed good safety of the PPV23 vaccine candidate produced by Ab&b Biotechnology Co., Ltd.JS had good safety after vaccination in people aged 2 years and older. At the same time, good immunogenicity was also demonstrated.
引用
- Zhang Y, Wang Y, Li G, et al. A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and older. Vaccine. 2024. PMID: 38519344. doi:10.1016/j.vaccine.2024.03.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。